-+ 0.00%
-+ 0.00%
-+ 0.00%
Summit Therapeutics' shares fell 29%; its lung cancer drug was rejected by the FDA.
Share
Listen to the news
Summit Therapeutics' shares fell 29%; its lung cancer drug was rejected by the FDA.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending